Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $4,362 - $4,759
59 Added 28.64%
265 $19,000
Q2 2023

Aug 09, 2023

BUY
$76.01 - $86.7 $15,658 - $17,860
206 New
206 $15,000
Q4 2022

Feb 13, 2023

SELL
$62.32 - $89.47 $19,443 - $27,914
-312 Reduced 89.14%
38 $3,000
Q3 2022

Nov 10, 2022

SELL
$59.54 - $68.01 $139,323 - $159,143
-2,340 Reduced 86.99%
350 $22,000
Q2 2022

Aug 08, 2022

SELL
$57.72 - $65.01 $95,353 - $107,396
-1,652 Reduced 38.05%
2,690 $166,000
Q1 2022

May 11, 2022

BUY
$57.92 - $72.58 $165,477 - $207,361
2,857 Added 192.39%
4,342 $258,000
Q4 2021

Feb 11, 2022

BUY
$64.88 - $73.64 $2,984 - $3,387
46 Added 3.2%
1,485 $108,000
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $67,893 - $73,249
-1,003 Reduced 41.07%
1,439 $101,000
Q2 2021

Aug 10, 2021

BUY
$63.47 - $69.35 $13,011 - $14,216
205 Added 9.16%
2,442 $168,000
Q1 2021

May 14, 2021

SELL
$60.0 - $68.46 $187,740 - $214,211
-3,129 Reduced 58.31%
2,237 $145,000
Q4 2020

Feb 12, 2021

BUY
$56.65 - $64.55 $47,132 - $53,705
832 Added 18.35%
5,366 $313,000
Q3 2020

Oct 30, 2020

SELL
$62.1 - $78.08 $132,148 - $166,154
-2,128 Reduced 31.94%
4,534 $287,000
Q2 2020

Aug 13, 2020

SELL
$72.34 - $84.0 $736,927 - $855,708
-10,187 Reduced 60.46%
6,662 $513,000
Q1 2020

May 15, 2020

BUY
$62.63 - $80.22 $25,490 - $32,649
407 Added 2.48%
16,849 $1.26 Million
Q4 2019

Feb 14, 2020

BUY
$61.62 - $67.78 $1.01 Million - $1.11 Million
16,442 New
16,442 $1.07 Million
Q1 2019

May 10, 2019

SELL
$62.53 - $70.05 $748,546 - $838,568
-11,971 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $59,147 - $77,183
977 Added 8.89%
11,971 $749,000
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $783,652 - $867,646
10,994 New
10,994 $849,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Rock Creek Group, LP Portfolio

Follow Rock Creek Group, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Creek Group, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Creek Group, LP with notifications on news.